Holland Foundation for Sight Restoration launched to provide life-changing eye surgeries
July 23, 2021
This announcement was made at the 2021 ASCRS annual meeting.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
All News
Catching up on new innovations for Allergan, an AbbVie company
July 23, 2021
Jag Dosanjh, senior vice president of U.S. Eye Care, Allergan, an AbbVie company, offers a preview of the company's latest innovations, developments, and what attendees can look forward to at ASCRS 2021.
COVID-19 has changed surgical preferences
July 23, 2021
A new report has found that glaucoma specialists’ procedure of choice has changed as a result of the COVID-19 pandemic.
CMS 2022 Physician Fee Schedule includes payment cut
July 19, 2021
AAO, Surgical Care Coalition teaming up to ensure the final version of the rule is fair to ophthalmologists and surgeons as one company is expressing its disappointment in the proposal.
First patient dosed in optogenetic gene therapy trial
July 19, 2021
Nanoscope Therapeutics Inc. has dosed its first patient in a late-stage Phase 2b trial of a gene therapy that delivers multi-characteristic opsin to retinal cells.
OCT may have role in treatment of neurofibromatosis type 1
July 15, 2021
The Gilbert Family Foundation is collaborating with the Children’s Oncology Group and Children’s Hospital of Philadelphia to validate a tool to measure progressive vision loss.
CRISPR-Cas13b prevents SARS-CoV-2 transmission in laboratory study
July 15, 2021
Australian researchers reported investigating the potential use of CRISPR, the gene-editing technology, to stop SARS-CoV-2 virus transmission in infected human cells.
FDA grants Investigational Device Exemption for MINIject in glaucoma patients
July 15, 2021
According to iSTAR Medical, the STAR-V study will investigate the device in 350 patients with primary open angle glaucoma.
Breakthrough Therapy Designation granted by FDA for Alkeus Pharmaceuticals’ ALK-001 Stargardt disease treatment
July 14, 2021
Alkeus Pharmaceuticals, Inc, announced Thursday that the FDA has granted Breakthrough Therapy Designation (BTS) for ALK-001 (C20-D3-vitamin A) for the treatment of Stargardt disease.
Are first signs of COVID-19 seen in the retina?
July 13, 2021
A team of investigators has found that the retina could offer signs of possible COVID-19 infection before they appear in other parts of the body.